![](https://webarchive.library.unt.edu/eot2008/20090201132621im_/http://www.cancer.gov/images/spacer.gif) |
|
Pancreatic Cancer Trial Results
1. Gemcitabine after Pancreatic Cancer Surgery Improves Survival (Posted: 06/24/2008) - Patients who received the chemotherapy drug gemcitabine after surgery for pancreatic cancer lived two months longer than patients who had surgery alone, according to findings presented at the 2008 ASCO meeting in Chicago.
![](https://webarchive.library.unt.edu/eot2008/20090201132621im_/http://www.cancer.gov/images/spacer.gif)
2. Gemcitabine Plus Standard Chemoradiation Improves Survival in Patients with Pancreatic Head Tumors (Posted: 06/05/2006) - Adding gemcitabine to a standard chemoradiation regimen improved overall survival in patients with the most common kind of pancreatic tumors: those located in the head of the pancreas, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
![](https://webarchive.library.unt.edu/eot2008/20090201132621im_/http://www.cancer.gov/images/spacer.gif)
3. Erlotinib Plus Gemcitabine Boosts One-Year Survival in Pancreatic Cancer (Posted: 05/14/2005, Reviewed: 10/06/2007) - Patients with advanced pancreatic cancer who were treated with the drug erlotinib (Tarceva®) in addition to gemcitabine had modest improvement in one-year survival rates compared to patients treated with gemcitabine alone, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
|
|
![](https://webarchive.library.unt.edu/eot2008/20090201132621im_/http://www.cancer.gov/images/spacer.gif) |